Normal view MARC view ISBD view

Acute lymphoblastic leukemia in infancy

In Pediatric Blood and Cancer
By: Silverman LB.
Contributor(s): lewis_silverman@dfci.harvard.edu.
Material type: materialTypeLabelArticleSeries: Vol 49 Issues 7.Publisher: 2007Description: 1070-1073.Subject(s): lymphoblastic | leukemia | infant | DDC classification: In: Pediatric Blood and CancerSummary: Infant ALL is uncommon, biologically distinctive from the disease in older children, and associated with a relatively poor prognosis. Adverse prognostic factors include the presence of an MLL gene rearrangement (observed in up to 80% of infants with ALL), younger age at diagnosis, high presenting leukocyte counts, and slow early response to therapy. The role of stem cell transplant in first remission remains controversial. Current research efforts to improve the outcome of MLL-rearranged ALL in infants include clinical trials testing cytarabine-intensive regimens and translational investigations of novel, targeted therapies, such as FLT3-inhibitors.
Tags from this library: No tags from this library for this title. Add tag(s)
Log in to add tags.
    average rating: 0.0 (0 votes)
Item type Current location Call number Status Date due Barcode
Articles Articles Tata Memorial Hospital
Available AR7591

Infant ALL is uncommon, biologically distinctive from the disease in older children, and associated with a relatively poor prognosis. Adverse prognostic factors include the presence of an MLL gene rearrangement (observed in up to 80% of infants with ALL), younger age at diagnosis, high presenting leukocyte counts, and slow early response to therapy. The role of stem cell transplant in first remission remains controversial. Current research efforts to improve the outcome of MLL-rearranged ALL in infants include clinical trials testing cytarabine-intensive regimens and translational investigations of novel, targeted therapies, such as FLT3-inhibitors.

There are no comments for this item.

Log in to your account to post a comment.

Powered by Koha